Mechanisms of action of cognitive enhancers on neuroreceptors.

No strategies for curing Alzheimer's disease have been developed yet as we do not know the exact cause of the disease. The only therapy that is available for patients is symptomatic treatment. Since Alzheimer's disease is associated with downregulation of the cholinergic system in the brain, its stimulation is expected to improve the patients' cognition, learning, and memory. Four anticholinesterases have been approved in the U.S.A. for the treatment of Alzheimer's disease patients. However, because of the inhibition of cholinesterases, these drugs have side effects and their effectiveness does not last long. Thus new approaches are needed. One approach is to stimulate directly nicotinic acetylcholine (nACh) receptors in the brain, and another is to stimulate NMDA receptors which are also known to be downregulated in Alzheimer's patients. Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM. This effect was exerted via G(s) proteins. The alpha7 receptor was almost unaffected by nefiracetam. Nefiracetam also potentiated NMDA currents with the maximum effect at 10 nM via interaction with the glycine-binding site of the receptor. Galantamine had a moderate potentiating effect on the alpha4beta2 receptor and potentiated NMDA currents with the maximum effect at 1 microM. However, galantamine did not interact with the glycine-binding site. Donepezil, a potent anticholinesterase, also potentiated NMDA currents at 1-10000 nM. In conclusion, these three drugs potentiate the activity not only of the cholinergic system but also of the NMDA system, thereby stimulating the downregulated nACh receptors and NMDA receptors to improve patients' learning, cognition, and memory.

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  S. Moriguchi,et al.  Mechanism of Action of Galantamine on N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  S. Moriguchi,et al.  Potentiation of N-Methyl-d-aspartate-Induced Currents by the Nootropic Drug Nefiracetam in Rat Cortical Neurons , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  Katrin Engelmann,et al.  cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner , 2002, Oncogene.

[5]  H. Eisenberg,et al.  The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. , 2002, Molecular pharmacology.

[6]  J. Lindstrom,et al.  Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. , 2001, Molecular pharmacology.

[7]  A. Maelicke,et al.  Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease , 2001, Biological Psychiatry.

[8]  G. Enikolopov,et al.  The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors. , 2000, Brain research. Molecular brain research.

[9]  A. Maelicke,et al.  Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. , 2000, European journal of pharmacology.

[10]  T. Nishizaki,et al.  A `long-term-potentiation-like' facilitation of hippocampal synaptic transmission induced by the nootropic nefiracetam , 1999, Brain Research.

[11]  J. Mcculloch,et al.  123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. , 1997, Journal of psychiatric research.

[12]  B. Mlinar,et al.  Adrenocorticotropic hormone and cAMP inhibit noninactivating K+ current in adrenocortical cells by an A-kinase-independent mechanism requiring ATP hydrolysis , 1996, The Journal of general physiology.

[13]  S. Hashtroudi,et al.  d-Cycloserine enhances implicit memory in Alzheimer patients , 1996, Neurology.

[14]  S. Ikeda,et al.  VIP inhibits N-type Ca2+ channels of sympathetic neurons via a pertussis toxin-insensitive but cholera toxin-sensitive pathway , 1994, Neuron.

[15]  M. Yoshii,et al.  Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells , 1994, Brain Research.

[16]  D. Olton,et al.  D-cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats , 1994, Neurobiology of Aging.

[17]  J. Mendels,et al.  Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type , 1992, Journal of the American Geriatrics Society.

[18]  S. Hashtroudi,et al.  Glycine prodrug facilitates memory retrieval in humans , 1991, Neurology.

[19]  G. Handelmann,et al.  Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents , 1989, Pharmacology Biochemistry and Behavior.

[20]  J. Penney,et al.  Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding , 1987, Journal of neurochemistry.

[21]  Manjit,et al.  Neurology , 1912, NeuroImage.

[22]  T. Nishizaki,et al.  Presynaptic Nicotinic Acetylcholine Receptors As a Functional Target of Nefiracetam in Inducing a Long-lasting Facilitation of Hippocampal Neurotransmission , 2000, Alzheimer disease and associated disorders.

[23]  Y. Murashima,et al.  Cellular Mechanism of Action of Cognitive Enhancers: Effects of Nefiracetam on Neuronal Ca2+ Channels , 2000, Alzheimer disease and associated disorders.

[24]  T Narahashi,et al.  Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. , 1999, Molecular pharmacology.

[25]  T. Nishizaki,et al.  Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. , 1998, Molecular pharmacology.

[26]  E X Albuquerque,et al.  Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. , 1996, Molecular pharmacology.

[27]  G. Lynch,et al.  The nature and causes of hippocampal long-term potentiation. , 1990, Progress in brain research.